Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5032Carcinoma, Renal Cell 1579Urinary Bladder Neoplasms 1281Kidney Neoplasms 725Breast Neoplasms 644Neoplasms 633Carcinoma, Transitional Cell 493Carcinoma, Non-Small-Cell Lung 470Neoplasm Metastasis 469Melanoma 423Ovarian Neoplasms 403Colorectal Neoplasms 375Lung Neoplasms 334Pancreatic Neoplasms 263Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 226Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 216Head and Neck Neoplasms 193Squamous Cell Carcinoma of Head and Neck 189Carcinoma, Hepatocellular 170Endometrial Neoplasms 167Colonic Neoplasms 167Esophageal Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castrate Resistant Prostate Cancer (CRPC) × Genitourinary × Clear all
NCT00868595 2019-10-08

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

Phase 1 Completed
18 enrolled
Genitourinary

Castrate Resistant Prostate Cancer (CRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡